Not All PVR Reductions Are Created Equal: Lessons From the CADENCE Trial.

Authors

Giuseppe Locatelli, Francesco Bini, Marco Vicenzi

Published in

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

The CADENCE trial evaluated sotatercept in combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction (CpcPH-HFpEF). We analyzed the pathophysiological implications of the observed pulmonary vascular resistance (PVR) reduction.A hemodynamic comparison was conducted contrasting the mechanistic effects of sotaercept with conventional pulmonary vasodilators.In CADENCE, PVR and pressure reductions occurred without marked cardiac output augmentation, contrasting with flow-mediated recruitment typical of traditional vasodilators. Sotatercept-induced PVR reduction may reflect true vascular reverse remodeling rather than vasodilation, underscoring the need to discriminate resistance reduction mechanisms in CpcPHHFpEF.

PMID:
42962984
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.